Crinetics Pharmaceuticals (CRNX) Interest Expenses (2017 - 2026)

Crinetics Pharmaceuticals' Interest Expenses history runs 10 years deep, the most recent figure standing at $121.6 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 5977.95% year-over-year to $121.6 million in Q1 2026; TTM through Mar 2026 was $121.6 million, a 22041.89% increase from a year earlier, with the FY2025 full-year figure at $392.0 million, up 16.11% from the prior year.
• Interest Expenses grew to $121.6 million in Q1 2026 per CRNX's latest filing, from -$3.3 million in the prior quarter.
• Across five years, Interest Expenses topped out at $356.6 million in Q3 2024 and bottomed at -$3.3 million in Q4 2025.
• The 5-year median for Interest Expenses is $27.8 million (2022), against an average of $98.0 million.
• Across the five-year window, Interest Expenses sank 675.5% in 2024 and soared 5977.95% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $300000.0 in 2022, then tumbled by 166.67% to -$200000.0 in 2023, then sank by 675.5% to -$1.6 million in 2024, then sank by 113.15% to -$3.3 million in 2025, then jumped by 3776.92% to $121.6 million in 2026.
• Per Business Quant, the three latest CRNX Interest Expenses figures stand at $121.6 million (Q1 2026), -$3.3 million (Q4 2025), and $201.9 million (Q3 2025).